JOURNAL HOME CME HOME THIS MONTH PAST ISSUES ETOC COLLECTIONS
AUTHORS REVIEWERS EDITORIAL BOARD FEEDBACK RSS HELP
A&A International Anesthesia Research Society
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (4)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Price, S.
Right arrow Articles by Jaggar, S. I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Price, S.
Right arrow Articles by Jaggar, S. I.
Related Collections
Right arrow Cardiovascular
Right arrow Critical Care
Right arrow Blood

Anesth Analg 2005;101:325-327
© 2005 International Anesthesia Research Society
doi: 10.1213/01.ANE.0000159158.70532.D0

CARDIOVASCULAR ANESTHESIA

Recombinant Human Erythropoietin Use in a Critically Ill Jehovah’s Witness After Cardiac Surgery

Susanna Price, MBBS, MRCP, PhD, John R. Pepper, MChir, FRCS, and Siân I. Jaggar, MBBS, FRCA, MD

Departments of Anesthesia and Critical Care and Cardiothoracic Surgery, Royal Brompton Hospital, London, UK

Address correspondence and reprint requests to Siân Jaggar, MBBS, FRCA, MD, Royal Brompton Hospital, Sydney Street, London SW3 6NP. Address e-mail to s.jaggar{at}rbh.nthames.nhs.uk.

Complex cardiac surgery often requires blood transfusion. Some patients refuse transfusion, even when it is potentially life-threatening to do so. Although recombinant human erythropoietin (rhEPO) has been used to reduce the need for blood transfusion, it has been considered ineffective in critically ill patients. The time course of hematological responses in a Jehovah’s Witness patient with acute renal failure and severe cardiac disease suggests that a trial of rhEPO should be considered for salvage therapy in critically ill patients.




This article has been cited by other articles:


Home page
 Br J AnaesthHome page
V. Casati, A. D'Angelo, L. Barbato, D. Turolla, F. Villa, M. A. Grasso, A. Porta, and F. Guerra
Perioperative management of four anaemic female Jehovah's Witnesses undergoing urgent complex cardiac surgery
Br. J. Anaesth., September 1, 2007; 99(3): 349 - 352.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
The Society of Thoracic Surgeons Blood Conservatio, V. A. Ferraris, S. P. Ferraris, S. P. Saha, E. A. Hessel II, C. K. Haan, B. D. Royston, C. R. Bridges, R. S.D. Higgins, G. Despotis, et al.
Perioperative Blood Transfusion and Blood Conservation in Cardiac Surgery: The Society of Thoracic Surgeons and The Society of Cardiovascular Anesthesiologists Clinical Practice Guideline
Ann. Thorac. Surg., May 1, 2007; 83(5_Supplement): S27 - S86.
[Abstract] [Full Text] [PDF]


Lippincott, Williams & Wilkins Anesthesia & Analgesia® is published for the International Anesthesia Research Society® by Lippincott Williams & Wilkins and Stanford University Libraries' HighWire Press®. Copyright 2005 by the International Anesthesia Research Society. Online ISSN: 1526-7598   Print ISSN: 0003-2999 HighWire Press
Copyright © 2005 by the International Anesthesia Research Society.